BHC
Undervalued by 47.7% based on the discounted cash flow analysis.
Market cap | $3.00 Billion |
---|---|
Enterprise Value | $23.79 Billion |
Dividend Yield | $0 (0%) |
Earnings per Share | $-1.62 |
Beta | 0.75 |
Outstanding Shares | 368,400,000 |
Return on Equity | - |
---|---|
Return on Assets | - |
Return on Invested Capital | - |
P/E Ratio | 11.72 |
---|---|
PEG | -15.11 |
Price to Sales | 0.33 |
Price to Book Ratio | -8.15 |
Enterprise Value to Revenue | 2.51 |
Enterprise Value to EBIT | -18.29 |
Enterprise Value to Net Income | 69 |
Total Debt to Enterprise | 0.9 |
Debt to Equity | -18.32 |
No data
No data
Bausch Health Companies Inc. (NYSE/TSX: BHC) is a global company whose mission is to improve people's lives with our health care products. We develop, manufacture and market a range of pharmaceutical, medical device and over-the-counter ...